novo's oral semaglutide bests lilly and boehringer ingelheim's jardiance in phase 3, but questions remain. can this oral semaglutide bolster @novonordiskus's #diabetes franchise? $
https://t.co/dyr3vhms3c https://t.co/5qxxad5kbx